Antoni Ribas, MD

Antoni Ribas, MD

Cutaneous (Skin) Medical Oncology
Primary Location
Westwood Cancer Care
100 Medical Plaza
550
Los Angeles, California 90095
Phone
Fax
310-443-0477

About

Antoni Ribas, MD, PhD is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG. Trained at the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA. Dr Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA.

His NCI, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). He is an elected member of the American Society of Clinical Investigation (ASCI), the recipient of the AACR Richard and Hinda Rosenthal Award and a National Cancer Institute (NCI) Outstanding Investigator Award.

Education

Fellowship

UCLA School of Medicine, 2001
UCLA School of Medicine, 1998

Residency

Hospital Vall d'Hebron, 1994

Internship

Hospital Vall d'Hebron, 1991

Degree

Universidad de Barcelona, MD, 1990

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Research

Interests

As a physician-scientist, Dr. Ribas has a NIH and California State-funded laboratory where he conducts research focusing on adoptive cell transfer with T cell receptor (TCR) engineered lymphocytes, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF-targeted therapies and nanoparticle-siRNA therapeutics.

Publications

Selected Publications:
  1. Mark E. Davis, Jonathan E. Zuckerman, Chung Hang J. Choi, David Seligson, Anthony Tolcher, Christopher A. Alabi, Yun Yen, Jeremy D. Heidel, Antoni Ribas. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010 Apr 15; 464 (7291): 1067-70.
  2. Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C. Koya, Hane Lee, Zugen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F. Nelson, Grant A. McArthur, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo. Melanomas acquire resistance to V600EB-RAF inhibition by RTK upregulation or N-RAS mutation. Nature 2010; Dec 16; 468 (7326): 973-7.
  3. Fei Su, Amaya Viros, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Olivia Spleiss, Jorge S. Reis-Filho, Xiangju Kong, Richard C. Koya, Min Jung Kim, Robert Hayward, Matthew Martin, Hong Yang, Qiongqing Wang, Johannes Noe, Maryou Lambros, Felipe Geyer, Nathalie Dhomen, Ion Niculescu-Duvaz, Alfonso Zambon, Dan Niculescu-Duvaz, Natasha Preece, Lídia Robert, Nicholas J. Otte, Stephen Mok, Damien Kee, Yan Ma, Chao Zhang Gaston Habets, Elizabeth A. Burton, Bernice Wong, Hoa Nguyen, James L. Troy, Keith T. Flaherty, Paul B. Chapman, Rene Gonzalez, Thomas E. Hutson, Igor Puzanov, Brian Lestini, Keith B. Nolop, Richard J. Lee, Andrew K. Joe, Caroline J. Springer, Jeffrey A. Sosman, Grant A. McArthur, Roger S. Lo, Antoni Ribas*, Richard Marais*. RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors. *equal contribution as corresponding and senior authors. New England Journal of Medicine 2012 January 19; 366: 207-15.
  4. Jeffrey A. Sosman, Kevin B. Kim, Lynn Schuchter, Rene Gonzalez, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Donald Lawrence, Peter Hersey, Richard Kefford, Keith T. Flaherty, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, Keith B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine 2012 Feb 23; 366 (8): 707-14.
  5. Antoni Ribas, Richard Kefford, Margaret A. Marshall, Cornelius J.A. Punt, John B. Haanen, Maribel Marmol, Claus Garbe, Helen Gogas, Jacob Schachter, Gerald Linette, Vladimir M. Moiseyenko, Paul Lorigan, Kari L. Kendra, Janusz Rolski, Michele Maio, Uwe Trefzer, Michael Smylie, Grant A. McArthur, Brigitte Dreno, Paul D. Nathan, G. L. Cohen, Andrzej Mackiewicz, John M. Kirkwood, Jesus Gomez-Navarro, Bo Huang, Dmitri Pavlov, Axel Hauschild. A phase III randomized clinical trial comparing tremelimumab with standard of care chemotherapy in patients with advanced melanoma. Journal of Clinical Oncology 2013 Feb 10; 31 (5): 616-22.
  6. Chao Ma, Ann F Cheung, Thinle Chodon, Richard C Koya, Zhongqi Wu, Charles Ng, Owen N. Witte, David Baltimore, Bartosz Chmielowski, James S. Economou, Begonya Comin-Anduix, Antoni Ribas*, James R. Heath*. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. *equal contribution as corresponding and senior authors. Cancer Discovery 2013 Apr; 3 (4): 418-29.
  7. Kerstin Trunzer, Anna C. Pavlick, Lynn Schuchter, Rene Gonzalez, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschoss, Keith T. Flaherty, Kevin B. Kim, Jeffrey S. Weber, Peter Hersey, Richard Kefford, Donald Lawrence, Patrick Ott, Ravi Amaravadi, Karl Lewis, Igor Puzanov, Roger S. Lo, Astrid Koehler, Mark Kockx, Olivia Spleiss, Annette Schell-Steven, Louise Cockey, Gideon Bollag, Richard Lee, Andrew Joe, Jeffrey A. Sosman, Antoni Ribas. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of Clinical Oncology 2013 May 10; 31 (14): 1767-74.
  8. Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss-Schaap, Alain Algazi, Christine Mateus, Peter Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot W. Ebbinghaus, Xiaoyun (Nicole) Li, S. Peter Kang, Antoni Ribas. Safety and Tumor Responses with Lambrolizumab (Anti PD-1) in Melanoma. New England Journal of Medicine 2013 Jul 11; 369 (2): 134-44.
  9. Thinle Chodon, Begonya Comin-Anduix, Bartosz Chmielowski, Richard C Koya, Zhongqi Wu, Charles Ng, Earl Avramis, Elizabeth Seja, Arturo Villanueva, Tara A. McCannel, Akira Ishiyama, Johannes Czernin, Martin Auerbach, Xiaoyan Wang, David W. Gjertson, Kenneth G. Cornetta, Deborah J.L. Wong, Omid Hamid, Wolfram Samlowski, Peter A. Cohen, Gregory A. Daniels, Jerome A. Zack, Donald B. Kohn, James R. Heath, John A. Glaspy, Owen N. Witte, David Baltimore, James S. Economou, Antoni Ribas. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clinical Cancer Research 2014; 20: 2457-65.
  10. Antoni Ribas, Rene Gonzalez, Anna Pavlick, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Adil Daud, Lawrence Flaherty, Theodore Logan, Bartosz Chmielowski, Karl Lewis, Damien Kee, Peter Boasberg, Ming Yin, Iris Chan, Nicholas Choong, Grant McArthur. Combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib in patients with advanced BRAFV600- mutated melanoma. The Lancet Oncology 2014 Aug; 15 (9): 954-65.
  11. Caroline Robert*, Antoni Ribas*, Jedd D. Wolchok, F. Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S. Weber, Anthony M. Joshua, Wen-Jen Hwu, Tara C. Gangadhar, Amita Patnaik, Roxana Dronca, Hassane Zarour, Richard W. Joseph, Peter Boasberg, Bartosz Chmielowski, Christine Mateus, Michael A. Postow, Kevin Gergich, Jeroen Elassaiss-Schaap, Xiaoyun (Nicole) Li, Robert Iannone, Scot W. Ebbinghaus, S. Peter Kang, Adil Daud. *equal contribution. Anti–PD-1 Treatment with MK-3475 in Ipilimumab-Refractory Advanced Melanoma. The Lancet 2014 Sep 20; 384 (9948): 1109-17.
  12. James Larkin, Paolo A. Ascierto, Brigette Dréno, Victoria Atkinson, MD, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Thomas, Luis de la Cruz Merino, Caroline Dutriaux, Claus Garbe, Ilsung Chang, Nicholas Choong, Stephen P. Hack, Grant A. McArthur, Antoni Ribas. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. New England Journal of Medicine 2014 Nov 13; 371 (20): 1867-76.
  13. Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. Taylor, Lidia Robert, Bartosz Chmielowski, Alisha N. West, Marko Spasic, Gina Henry, Voicu Ciobanu, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio Gutierrez, Tristan R. Grogan, John A. Glaspy, Ryan Emerson, Harlan Robins, Robert Pierce, David A. Elashoff, Caroline Robert, Antoni Ribas. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014 Nov 26; 515 (7528): 568-71.
  14. Mohammad Atefi, Bjoern Titz, Earl Avramis, Charles Ng, Deborah Wong, Amanda Lassen, Michael Cerniglia, Helena Escuin-Ordinas, David Foulad, Begonya Comin-Anduix, Thomas G. Graeber, Antoni Ribas. Combination of pan-RAF and MEK inhibitors to block growth of NRAS mutant melanoma cell lines. Molecular Cancer 2015 Mar; 25 (3): 399-400.
  15. Caroline Robert, Jacob Schachter, Georgina V. Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S. Carlino, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira-Frommer, Michele Kosh, Honghong Zhou, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas. Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine 2015 Jun 25; 372 (26): 2521-32.
  16. Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven J. O’Day, Paolo A. Ascierto, April K.S. Salama, Kim A. Margolin, Carmen Loquai, Thomas K. Eigentler, Tara C. Gangadhar, Matteo S. Carlino, Sanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira-Frommer, Rene Gonzalez, John M. Kirkwood, Jedd D. Wolchok, Alexander Eggermont, Xiaoyun (Nicole) Li, Wei Zhou, Adriane M. Zernhelt, Joy Lis, Scot Ebbinghaus, S. Peter Kang, Adil Daud. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma: a randomised, open-label trial. Lancet Oncology 2015 Jun 23. pii: S1470-2045 (15) 00083-2.
  17. Antoni Ribas, Omid Hamid, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Richard Kefford, Anthony M. Joshua, Amita Patnaik, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Peter Hersey, Roxana Dronca, Richard W. Joseph, Hassane Zarour, Bartosz Chmielowski, Donald P. Lawrence, Alain Algazi, Naiyer A. Rizvi, Brianna Hoffner, Christine Mateus, Kevin Gergich, Jill A. Lindia, Maxine Giannotti, Xiaoyun (Nicole) Li, Scot Ebbinghaus, S. Peter Kang, Caroline Robert. Association of Pembrolizumab Administration with Tumor Response and Survival Among Patients with Advanced Melanoma. Journal of the American Medical Association (JAMA) 2016 Apr 19; 315 (15): 1600-9.
  18. Jesse Zaretsky, Angel Garcia Diaz, Daniel Sanghoon Shin, Helena Escuin-Ordinas, Siwen Hu-Lieskovan, Blanca Homet Moreno, Willy Hugo, Davis Y. Torrejon, Gabriel Abril Rodriguez, Salemiz Sandoval, Lucas Barthly, Justin Saco, Riccardo Mezzadra, Bartosz Chmielowski, Katherine Ruchalski, Lidia Robert, Grace Cherry1, Elizabeth Seja, Beata Berent-Maoz1, Begonya Comin-Anduix, Thomas G. Graeber, Paul C. Tumeh, Ton N.M. Schumacher, Roger S. Lo, Antoni Ribas. Mutations associated with acquired resistance to PD-1 blockade in melanoma. New England Journal of Medicine 2016 ePub July 13, 2016.

Awards

  • 2016 AACR Richard and Hinda Rosenthal Memorial Award
  • 2015 Member of the Royal Academy of Medicine of Catalonia.
  • 2015 Lila and Murray Gruber Memorial Cancer Research Award and Lectureship, American Academy of Dermatology (AAD).
  • 2015 Giants of Cancer Award, OncLife.
  • 2015 R35 Outstanding Researcher Award, NIH-NCI.
  • 2013 Outstanding Research Award, Society for Melanoma Research (SMR).
  • 2013 Physician of the Year, Melanoma International Foundation.
  • 2009 Elected member of the American Society of Clinical Investigation (ASCI).
  • 2008 New Faculty Award from the California Institute of Regenerative Medicine (CIRM).
  • 2005 Melanoma Research Foundation Junior Researcher Award.
  • 2002 Stop Cancer Career Development Award.
  • 2002 K23 CA93376 Career Development Award.
  • 2000 Clinical Research Career Development Award from the American Society of Clinical Oncology (ASCO).
  • 2000 Amgen Oncology Fellow Award. 2000 Fellow Teaching Award, UCLA.
  • 1997 Extraordinary Prize and Suma Cum Laude, Doctoral Thesis. Autonomous University of Barcelona.